Evidence map›Paper›PMID 34439113›Full record

ArticleCancers2021

Survival and Death Causes in Thyroid Cancer in Taiwan: A Nationwide Case-Control Cohort Study.

Yu-Ling Lu, Shu-Fu Lin, Ming-Hsien Wu, Yi-Yin Lee, Pai-Wei Lee, Shang-Hung Chang, Yu-Tung Huang

Abstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yu-Ling LuDepartment of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei City 230617, Taiwan.
Shu-Fu LinDepartment of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei City 230617, Taiwan.ORCID 0000-0001-8877-9685
Ming-Hsien WuDepartment of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei City 230617, Taiwan.ORCID 0000-0003-4580-550X
Yi-Yin LeeDepartment of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei City 230617, Taiwan.
Pai-Wei LeeCenter for Big Data Analytics and Statistics, Chang Gung Memorial Hospital, Linkou Main Branch, Taoyuan City 333423, Taiwan.
Shang-Hung ChangSchool of Medicine, College of Medicine, Chang Gung University, Taoyuan City 333323, Taiwan.
Yu-Tung HuangCenter for Big Data Analytics and Statistics, Chang Gung Memorial Hospital, Linkou Main Branch, Taoyuan City 333423, Taiwan.ORCID 0000-0003-3224-7238

Funding

Chang Gung Medical Foundation CMRPVVK0022
6 · The paper itself

Abstract

The incidence of thyroid cancer has increased substantially worldwide. However, the overall mortality risk and actual causes of death in thyroid cancer patients have not been extensively evaluated. In this study, patients with thyroid cancer diagnosed between 2001 and 2017 were analyzed from Taiwan's National Health Insurance Research Database. We compared these patients with control subjects matched for age, gender, history of cardiovascular disease (CVD), hyperlipidemia, diabetes mellitus, hypertension, and occupation to assess the risk of overall mortality and cause-specific mortality. Finally, our cohort comprised 30,778 patients with thyroid cancer. Three hundred and ninety-eight deaths (1.29%) occurred during a median follow-up of 60.0 months (range: 30.3 to 117.6 months). The primary cause of death was thyroid cancer mortality (31.2%), followed by other malignancy-related mortality (29.9%) and CVD mortality (12.3%). The overall mortality risk was similar between the thyroid cancer and control groups (unadjusted hazard ratio (HR): 0.98; 95% confidence interval (CI): 0.88-1.10); the adjusted HR was 1.07 (95% CI: 0.95-1.20) after multivariate adjustment for age, gender, history of CVD, hyperlipidemia, diabetes mellitus, hypertension, and occupation. The risk of other malignancy-related mortality was comparable between two groups. CVD mortality risk was lower in the thyroid cancer group, with an unadjusted HR of 0.51 (95% CI: 0.38-0.69) and adjusted HR of 0.56 (95% CI: 0.42-0.76). In conclusion, patients with thyroid cancer had excellent overall survival. Thyroid cancer-specific mortality was the leading cause of death, highlighting the importance of thyroid cancer management. Thyroid cancer patients had lower CVD mortality risk than the general population.

Indexed as

causes of deathsurvivalTaiwanthyroid cancer

Identifiers

PMID34439113
PMCPMC8391882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.